Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F

PLoS ONE

Volumn 1, Issue 1, 2006, Pages

  Zaleskas, Virginia M ^a   Krause, Daniela S ^a,c   Lazarides, Katherine ^a   Patel, Nihal ^a   Hu, Yiguo ^b   Li, Shaoguang ^b   Van Etten, Richard A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b JACKSON LABORATORY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; HEMATOPOIETIC CELL KINASE; HEMOGLOBIN; IMATINIB; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; JAK2 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; BURST FORMING UNIT E; CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; GENETIC TRANSDUCTION; HEMATOCRIT; HEMATOPOIETIC SYSTEM; HEMOGLOBIN DETERMINATION; LEUKOCYTOSIS; MEGAKARYOCYTE; MOUSE; MOUSE STRAIN; MYELOFIBROSIS; NEUTROPHILIA; NONHUMAN; PATHOGENESIS; POLYCYTHEMIA; PROTEIN BLOOD LEVEL; RETICULOCYTOSIS; SPLEEN DISEASE; SPLENOMEGALY; THROMBOCYTE COUNT; AMINO ACID SUBSTITUTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; ERYTHROPOIESIS; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; MYELOID METAPLASIA; PATHOLOGY; POINT MUTATION; POLYCYTHEMIA VERA;

MURINAE; MUS;

AMINO ACID SUBSTITUTION; ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ERYTHROPOIESIS; HUMANS; JANUS KINASE 2; LEUKOCYTOSIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET COUNT; POINT MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC;

EID: 34447642422     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000018     Document Type: Article

References (48)

1. Dameshek W (1951) Some speculations on the myeloproliferative disorders. Blood 6: 372-375.
2. Van Etten RA, Shannon KM (2004) Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6: 547-552.
3. bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
5. Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100: 4272-4290.
6. Prchal JF, Axelrad AA (1974) Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 290: 1382.
7. Correa PN, Eskinazi D, Axelrad AA (1994) Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 83: 99-112.
8. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, et al. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95: 2569-2576.
9. Moliterno AR, Hankins WD, Spivak JL (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338: 572-580.
10. Xu MJ, Sui X, Zhao R, Dai C, Krantz SB, et al. (2003) PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood 102: 4354-4360.
11. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
12. Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, et al. (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32: 179-187.
13. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
14. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
15. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
16. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
17. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168.
18. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, et al. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106: 1207-1209.
19. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, et al. (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106: 2920-2921.
20. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
21. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, et al. (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5: 287-298.
22. Meng F, Lowell CA (1997) Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med 185: 1661-1670.
23. Friedman JS, Rebel VI, Derby R, Bell K, Huang T-T, et al. (2001) Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. J Exp Med 193: 925-934.
24. Ramakrishnan V, Reeves PS, DeGuzman F, Deshpande U, Ministri-Madrid K, et al. (1999) Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci USA 96: 13336-13341.
25. Drachman JG, Sabath DF, Fox NE, Kaushansky K (1997) Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 89: 483-492.
26. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, et al. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105: 3995-4003.
27. Shah NP, Tran C, Lee FY, Chen P, Norrris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
28. Richmond TD, Chohan M, Barber DL (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends Biochem Sci 15: 146-155.
29. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, et al. (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36: 453-461.
30. Ingley E, McCarthy DJ, Pore JR, Sarna MK, Adenan AS, et al. (2005) Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene 24: 336-343.
31. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, et al. (2005) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107: 3339-3341.
32. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, et al. (2002) Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 12: 1219-1223.
33. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648.
34. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792.
35. Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, et al. (2006) Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med 125: 253-264.
36. Lu X, Levine R, Tong W, Wernig G, Pikman Y, et al. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102: 18962-18967.
37. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, et al. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281.
38. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, et al. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652-1660.
39. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL (2005) The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 130: 800-801.
40. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, et al. (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108: 346-352.
41. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, et al. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631-635.
42. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, et al. (2006) X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107: 4139-4141.
43. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366: 1945-1953.
44. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, et al. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107: 2098-2100.
45. Westervelt P, Ley TJ (1999) Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood 93: 2143-2148.
46. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473-481.
47. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, et al. (2001) Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98: 3261-3273.
48. Xie S, Lin H, Sun T, Arlinghaus RB (2002) Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21: 7137-7146.